What are Ki‑67 hot spots?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ki-67 Hot Spots in Breast Cancer

Ki-67 hot spots are focal areas within a tumor where Ki-67 immunohistochemical staining is particularly prevalent, showing markedly higher proliferative activity compared to the surrounding tumor tissue. 1

Definition and Characteristics

Ki-67 hot spots represent regions of biological heterogeneity within breast cancer specimens where the percentage of proliferating cells is substantially elevated. 1 These areas can occur even in otherwise homogeneously stained samples, creating significant variability in scoring—for example, one area might show approximately 30% Ki-67 positivity while a hot spot in the same tumor could demonstrate approximately 90% positivity. 1

Clinical Context and Biological Significance

Hot spots are one of two prominent types of heterogeneity observed in Ki-67 staining patterns, the other being a gradient of increasing staining toward the tumor edge. 1 The invasive edge is generally considered the most biologically active part of the tumor and most likely to drive disease outcome. 1

Scoring Controversy and Current Recommendations

The approach to handling hot spots remains controversial in clinical practice:

  • Some investigators focus specifically on analyzing hot spots 1
  • Others include hot spots within a general assessment across the entire section 1
  • Yet others recommend avoiding hot spots altogether 1

Standardized Approach

The International Ki67 in Breast Cancer Working Group recommends that when hot spots are present, pathologists should assess the whole section and record the overall average score for consistency. 1 This recommendation prioritizes reproducibility over potentially capturing the most aggressive tumor biology, as the optimal method remains under investigation by a dedicated working party. 1

Practical Scoring Implications

When performing Ki-67 assessment:

  • Count at least 1000 tumor cells (minimum 500 cells) across representative fields 1
  • Score at least three randomly selected high-power (×40 objective) fields if staining is homogeneous 1
  • For heterogeneous specimens with hot spots, average the score across the entire section rather than focusing exclusively on high-proliferation areas 1

Research Perspectives on Hot Spot Analysis

Recent studies have explored computational methods for identifying Ki-67 hot spots, with clustering algorithms developed to help pathologists quantitatively characterize these high-proliferation patterns. 2 Some research suggests that hot spot scoring may have greater prognostic potential for recurrence-free survival (hazard ratio 6.88) compared to global scoring (hazard ratio 3.13), though global scoring performed better for overall survival prediction. 3

However, standardization efforts have shown that analyzing hot spots on light microscopy yields only moderate agreement (Fleiss' kappa 0.48 at 20% cut-off), similar to other methods. 4

Common Pitfalls

  • Focusing exclusively on hot spots can lead to overestimation of tumor proliferative activity 1
  • Inconsistent hot spot selection contributes to inter-observer variability 1
  • Digital image analysis may identify different hot spot locations than visual assessment, with higher Ki-67 percentages in the first 100-200 cells counted 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.